Bain Capital Investors LLC Sells 1,846,887 Shares of Kestra Medical Technologies, Ltd. $KMTS

Bain Capital Investors LLC cut its position in Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) by 6.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 25,172,338 shares of the company’s stock after selling 1,846,887 shares during the period. Kestra Medical Technologies comprises about 14.4% of Bain Capital Investors LLC’s portfolio, making the stock its 3rd largest position. Bain Capital Investors LLC owned approximately 0.43% of Kestra Medical Technologies worth $667,570,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of KMTS. Franklin Resources Inc. raised its holdings in Kestra Medical Technologies by 180.8% in the fourth quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock worth $25,221,000 after purchasing an additional 612,343 shares during the period. Millennium Management LLC acquired a new stake in Kestra Medical Technologies in the first quarter worth $11,036,000. Brown Advisory Inc. raised its holdings in Kestra Medical Technologies by 34.1% in the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock worth $44,775,000 after purchasing an additional 428,996 shares during the period. Geode Capital Management LLC raised its holdings in Kestra Medical Technologies by 718.5% in the second quarter. Geode Capital Management LLC now owns 325,326 shares of the company’s stock worth $5,395,000 after purchasing an additional 285,579 shares during the period. Finally, Next Century Growth Investors LLC raised its holdings in Kestra Medical Technologies by 154.5% in the fourth quarter. Next Century Growth Investors LLC now owns 465,845 shares of the company’s stock worth $12,354,000 after purchasing an additional 282,832 shares during the period.

Insider Activity at Kestra Medical Technologies

In related news, insider Brian Daniel Webster sold 15,000 shares of the firm’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $20.96, for a total transaction of $314,400.00. Following the sale, the insider directly owned 334,786 shares in the company, valued at $7,017,114.56. This trade represents a 4.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 3.60% of the stock is currently owned by insiders.

Kestra Medical Technologies Trading Down 5.8%

Shares of NASDAQ:KMTS opened at $19.23 on Wednesday. Kestra Medical Technologies, Ltd. has a 12 month low of $13.25 and a 12 month high of $30.00. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.15. The company’s fifty day simple moving average is $20.70 and its 200 day simple moving average is $22.97. The firm has a market cap of $1.12 billion, a price-to-earnings ratio of -4.86 and a beta of 0.83.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.The company had revenue of $24.55 million for the quarter. The company’s revenue for the quarter was up 62.7% compared to the same quarter last year. As a group, research analysts forecast that Kestra Medical Technologies, Ltd. will post -2.34 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on KMTS. BTIG Research reiterated a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a report on Tuesday, April 7th. The Goldman Sachs Group cut their target price on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Finally, Weiss Ratings lowered shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Kestra Medical Technologies currently has a consensus rating of “Hold” and an average price target of $27.40.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.